Business
Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH
Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today signed an agreement to invest in a majority share (51% of the shares) in privately owned Streifeneder ortho.production GmbH ("Streifeneder"). Today Streifeneder ortho.production is part of Streifeneder KG (Group), a supplier of orthopaedic solutions and operator of a large O&P clinic network in Bayern, Germany.
About this update from Embla Medical Hf
[{"type":"text","content":"Announcement no. 31/2025","length":24,"tagName":"p"},{"type":"text","content":"17 July 2025","length":12,"tagName":"p"},{"type":"text","content":"REYKJAVIK, Iceland and COPENHAGEN, Denmark, July 17, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today signed an agreement to invest in a majority share (51% of the shares) in privately owned Streifeneder ortho.production GmbH ("Streifeneder"). Today Streifeneder ortho.production is part of Streifeneder KG (Group), a supplier of orthopaedic solutions and operator of a large O&P clinic network in Bayern, Germany.","length":518,"tagName":"p"},{"type":"text","content":"Streifeneder is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people. In addition to its offerings of prosthetic and orthotic components, Streifeneder also supplies orthopaedic materials and equipment to the O&P industry. In 2024, Streifeneder realized sales of EUR 25 million (approximately USD 29m) with ~70% of sales related to prosthetics and orthopaedic materials. The majority of sales are generated in Germany, while also selling into other key European markets and distributing into the Americas and APAC regions.","length":575,"tagName":"p"},{"type":"text","content":"The investment in Streifeneder represents an attractive opportunity for Embla Medical to become a full range provider to a larger part of the global O&P market, ultimately reaching more patients. The majority investment in Streifeneder will furthermore strengthen Embla Medical's presence in Germany, the second largest O&P market in the world. Streifeneder is estimated to grow in line with the global prosthetics market in the range of 5-7% in the near-term, in addition to realizing commercial synergies by leveraging Embla Medical/Össur's global footprint.","length":576,"tagName":"p"},{"type":"text","content":"The closing of the transaction is subject to regulatory approvals.","length":66,"tagName":"p"},{"type":"text","content":"Sveinn Sölvason, President and CEO of Embla Medical, said:","length":58,"tagName":"p"},{"type":"text","content":""The investment in Streifeneder is a strong strategic fit with our Growth'27 strategy and will enable Embla Medical to reach more patients with ...